Canadian Cohort of Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH).

Launched by CAN-AM HIFU INC. · Jan 7, 2022

Keywords

ClinConnect Summary

This clinical trial, called the Canadian Cohort of Convective Thermal Therapy Using the Rezūm System, is studying a treatment for men with Benign Prostatic Hyperplasia (BPH), which is a common condition where the prostate gland becomes enlarged and can cause urinary problems. The trial aims to document how well this Rezūm therapy works for patients in Canada.

To participate, men must be at least 18 years old and have a diagnosis of BPH. They should be considered suitable candidates for the Rezūm treatment by their doctor. Participants will need to complete some questionnaires about their health and must be willing to sign consent forms to take part in the study. If someone has health issues that could interfere with the study or if they can't follow the study rules, they may not be eligible. Those who join the trial can expect to receive the Rezūm therapy and help researchers understand its effectiveness for treating BPH.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male subjects of ≥ 18 years of age.
• • Primary diagnosis of Benign Prostate Hypertrophy (BPH).
• • Candidate for Rezūm therapy as per clinical decision of Investigator.
• • Willing and able to accurately complete the required questionnaires.
• • Willing and able to provide signed and dated informed consent
• Exclusion Criteria:
• • Characteristics indicating a poor compliance with study protocol requirements.
• • Disease or other health condition that is not suitable for this study.
• • Unable or unwilling to provide signed informed consent.